$1,318.00
This Market Spotlight report covers the Idiopathic pulmonary fibrosis (IPF) market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Patient segmentation
7 Symptoms
7 Risk factors
8 Diagnosis
9 TREATMENT
9 Pharmacologic treatment
9 Non-pharmacologic treatments
11 EPIDEMIOLOGY
16 MARKETED DRUGS
18 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 GLPG1690 for IPF (July 14, 2019)
27 KEY UPCOMING EVENTS
28 PROBABILITY OF SUCCESS
29 LICENSING AND ASSET ACQUISITION DEALS
29 Reborn Redx Inks Global Licensing Deal With AstraZeneca
29 Galapagos Seeks IPF Discovery Leads From E-Therapeutics
29 Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
30 REVENUE OPPORTUNITY
31 CLINICAL TRIAL LANDSCAPE
32 Sponsors by status
33 Sponsors by phase
35 BIBLIOGRAPHY
36 Prescription information
37 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of IPF, 2019–28
15 Figure 2: Trends in prevalent cases of IPF, 2019–28
18 Figure 3: Overview of pipeline drugs for IPF in the US
18 Figure 4: Pipeline drugs for IPF, by company
19 Figure 5: Pipeline drugs for IPF, by drug type
19 Figure 6: Pipeline drugs for IPF, by classification
27 Figure 7: Key upcoming events in IPF
28 Figure 8: Probability of success in the IPF pipeline
31 Figure 9: Clinical trials in IPF
31 Figure 10: Top 10 drugs for clinical trials in IPF
32 Figure 11: Top 10 companies for clinical trials in IPF
32 Figure 12: Trial locations in IPF
33 Figure 13: IPF trials status
34 Figure 14: IPF trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of IPF, 2019–28
14 Table 2: Prevalent cases of IPF, 2019–28
17 Table 3: Marketed drugs for IPF
20 Table 4: Pipeline drugs for IPF in the US
25 Table 5: GLPG1690 for IPF (July 14, 2019)
30 Table 6: Historical global sales, by drug ($m), 2015–19
30 Table 7: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!